Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and TIL in Advanced NSCLC
NCT03215810Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2017
- Primary completion
- Feb 2021
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LN-145 in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Dose Limiting Toxicity at 40 months. Started Oct 2017; status: completed.
02
Drugs
LN-145
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03215810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215810.